Tarhini, A., Lin, Y., Lin, H., Rahman, Z., Vallabhaneni, P., Mendiratta, P., . . . Kirkwood, J. M. (2018). Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: Safety, efficacy and impact on T-cell repertoire. J Immunother Cancer.
シカゴスタイル引用形Tarhini, Ahmad, et al. "Neoadjuvant Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-α2b in Locally/regionally Advanced Melanoma: Safety, Efficacy and Impact On T-cell Repertoire." J Immunother Cancer 2018.
MLA引用形式Tarhini, Ahmad, et al. "Neoadjuvant Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-α2b in Locally/regionally Advanced Melanoma: Safety, Efficacy and Impact On T-cell Repertoire." J Immunother Cancer 2018.
警告: この引用は必ずしも正確ではありません.